Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about LLY, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Lebrikizumab FDA approved Sep 2024 · Ebglyss |
Atopic Dermatitis | Phase 4 · NCT07856134 | Not yet recruiting |
| Insulin Lispro-Aabc FDA approved Jun 2020 · Lyumjev |
Diabetes Mellitus, Type 2 | Phase 4 · NCT06370715 | Completed |
| Insulin Glargine FDA approved Dec 2015 · Basaglar |
Diabetes Mellitus, Type 2 | Phase 4 · NCT06370715 | Completed |
| Donanemab FDA approved Jul 2024 · Kisunla |
Alzheimer Disease | Phase 4 · NCT07838155 | Not yet recruiting |
| Mirikizumab FDA approved Oct 2023 · Omvoh |
Ulcerative Colitis (UC) | Phase 4 · NCT07686757 | Enrolling by invitation |
| Orforglipron FDA approved Apr 2026 · Foundayo |
Obesity | Phase 3 · NCT06672549 | Recruiting |
| Dulaglutide FDA approved Sep 2014 · Trulicity |
Diabetes Mellitus, Type 2 | Phase 3 · NCT07668336 | Not yet recruiting |
| Tirzepatide FDA approved May 2022 · Mounjaro |
Ulcerative Colitis | Phase 3 · NCT06937086 | Recruiting |
| Abemaciclib FDA approved Sep 2017 · Verzenio |
Brain Metastases | Phase 1/2 · NCT04923542 | Recruiting |
| Baricitinib FDA approved May 2018 · Olumiant |
Central Centrifugal Cicatricial Alopecia | Phase 2 · NCT07843732 | Completed |
| anti-integrin antibodies | Ulcerative Colitis (UC) | Phase 4 · NCT07686757 | Enrolling by invitation |
| Anti-TNF agents | Ulcerative Colitis (UC) | Phase 4 · NCT07686757 | Enrolling by invitation |
| Edodekin alfa | Ulcerative Colitis (UC) | Phase 4 · NCT07686757 | Enrolling by invitation |
| Lepodisiran Sodium | Atherosclerotic Cardiovascular Disease (ASCVD) | Phase 3 · NCT06292013 | Active not recruiting |
| Muvalaplin | Elevated Lp(a) | Phase 3 · NCT07157774 | Recruiting |
| Olomorasib (LY3537982) | Carcinoma, Non-Small-Cell Lung | Phase 3 · NCT06890598 | Recruiting |
Also used in these trials (approved or third-party drugs, not LLY's own candidates): Interleukin-23, Durvalumab, Pembrolizumab, Rituximab, Oral Semaglutide, Mosunetuzumab, Obinutuzumab, Venetoclax, Adagrasib, Brexucabtagene Autoleucel, Glofitamab, Fulvestrant.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
LLY holds $9B in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LLY files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| LILLY ENDOWMENT INC Former 10% Shareholder |
Insider | 90,376,978 | 9.60% | 2026-06-30 |
| Blackrock Inc. | Institution (13F) | 67,540,400 | 7.17% | 2026-06-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 61,295,605 | 6.51% | 2026-03-31 |
| PNC Financial Services Group, Inc. | Institution (13F) | 51,322,720 | 5.45% | 2026-06-30 |
| State Street Corporation | Institution (13F) | 36,215,754 | 3.85% | 2026-06-30 |
| FMR, LLC | Institution (13F) | 28,462,475 | 3.02% | 2026-06-30 |
| Capital Research Global Investors | Institution (13F) | 20,873,140 | 2.22% | 2026-06-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 20,859,217 | 2.22% | 2026-06-30 |
| Geode Capital Management, LLC | Institution (13F) | 20,310,858 | 2.16% | 2026-06-30 |
| Morgan Stanley | Institution (13F) | 16,226,398 | 1.72% | 2026-06-30 |
| Capital World Investors | Institution (13F) | 15,902,642 | 1.69% | 2026-06-30 |
| Eli Lilly and Company | 5%+ holder (13D) | 6,344,114 | 0.67% | 2026-01-12 |
Share count 941,357,065 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-09-21 filed 2026-09-22 |
Fyrwald J Erik |
Award (A) | 9 | $1,164.89 | 75,536 |
| 2026-09-21 filed 2026-09-22 |
Alvarez Ralph |
Award (A) | 11 | $1,164.89 | 55,838 |
| 2026-09-21 filed 2026-09-22 |
Sulzberger Gabrielle |
Award (A) | 4 | $1,164.89 | 3,012 |
| 2026-09-21 filed 2026-09-22 |
LUCIANO JUAN R |
Award (A) | 14 | $1,164.89 | 16,957 |
| 2026-09-09 filed 2026-09-11 |
Seymour Melissa |
Gift (G) | 12 | – | 1,038 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LLY and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →